143 related articles for article (PubMed ID: 17881638)
1. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Grandone E; Guardascione MA; Margaglione M
Blood; 2007 Oct; 110(7):2768-9. PubMed ID: 17881638
[No Abstract] [Full Text] [Related]
2. Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia.
Biagioni E; Pedrazzi P; Marietta M; Di Benedetto F; Villa E; Luppi M; Girardis M
J Thromb Thrombolysis; 2013 Oct; 36(3):352-4. PubMed ID: 23277116
[TBL] [Abstract][Full Text] [Related]
3. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
4. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
[No Abstract] [Full Text] [Related]
5. Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Wen H; Jin D; Chen Y; Cui B; Xiao T
BMC Neurol; 2021 Jun; 21(1):225. PubMed ID: 34134639
[TBL] [Abstract][Full Text] [Related]
6. Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene.
Helbig G; Wichary R; Torba K; Kyrcz-Krzemień S
Med Oncol; 2017 Mar; 34(3):31. PubMed ID: 28120162
[No Abstract] [Full Text] [Related]
7. JAK2 mutation in patients with splanchnic venous thrombosis: a pilot study from India.
Sazawal S; Rathi S; Chikkara S; Chaubey R; Seth T; Saraya A; Das J; Mahapatra M; Saxena R
Indian J Med Res; 2012 Mar; 135(3):429-31. PubMed ID: 22561633
[No Abstract] [Full Text] [Related]
8. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
[TBL] [Abstract][Full Text] [Related]
9. A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F.
Acharya A; Vaniawala S; Parekh H; Sheikh H; Patel H; Ali R; Khan A; Nagee A; Kunjadia P; Mukhopadhyaya PN
Int J Lab Hematol; 2014 Aug; 36(4):e30-3. PubMed ID: 24033912
[No Abstract] [Full Text] [Related]
10. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
11. Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2.
Bartels S; Faisal M; Büsche G; Schlue J; Kreipe H; Lehmann U
Leukemia; 2018 Feb; 32(2):556-558. PubMed ID: 28935989
[No Abstract] [Full Text] [Related]
12. B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
Jaitly V; Wang W
Blood; 2018 Feb; 131(8):941. PubMed ID: 29472375
[No Abstract] [Full Text] [Related]
13. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
[No Abstract] [Full Text] [Related]
14. JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.
Benedik-Dolničar M; Homan M; Brecelj J
J Pediatr Hematol Oncol; 2012 Apr; 34(3):243-4. PubMed ID: 21552144
[No Abstract] [Full Text] [Related]
15. [Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
Araki N; Takimoto R; Chiba H; Araki H; Sato T; Iyama S; Hirakawa M; Ono K; Kawano Y; Takada K; Miyanishi K; Kobune M; Matsunaga T; Kato J; Nakamura T; Niitsu Y
Rinsho Ketsueki; 2007 Jul; 48(7):554-8. PubMed ID: 17695304
[TBL] [Abstract][Full Text] [Related]
16. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
17. The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.
Jacobs J; Sharma D; Vnencak-Jones C
J Thromb Thrombolysis; 2022 Jan; 53(1):213-217. PubMed ID: 34240279
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.
Wang X; Tripodi J; Kremyanskaya M; Blouin A; Roda P; Hoffman R; Najfeld V
Blood; 2013 Feb; 121(7):1238-9. PubMed ID: 23411734
[No Abstract] [Full Text] [Related]
19. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
20. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
